Wells Fargo & Company Lowers argenex (NASDAQ:ARGX) Price Target to $1,247.00

argenex (NASDAQ:ARGX) had its price objective decreased by research analysts at Wells Fargo & Company from $1,317.00 to $1,247.00 in a research note issued on Friday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Wells Fargo & Company‘s price objective would suggest a potential upside of 62.60% from the company’s previous close.

Several other research firms also recently issued reports on ARGX. Guggenheim decreased their price objective on shares of argenex from $1,160.00 to $1,120.00 and set a “buy” rating for the company in a report on Friday. Morgan Stanley boosted their price objective on argenex from $1,070.00 to $1,110.00 and gave the stock an “overweight” rating in a research report on Thursday, December 4th. Piper Sandler increased their target price on argenex from $820.00 to $930.00 and gave the company an “overweight” rating in a research note on Tuesday, November 4th. Zacks Research raised argenex from a “strong sell” rating to a “hold” rating in a research report on Friday, February 20th. Finally, Stifel Nicolaus increased their price target on shares of argenex from $1,028.00 to $1,248.00 and gave the company a “buy” rating in a report on Thursday, December 11th. One analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $999.22.

argenex Stock Performance

ARGX opened at $766.92 on Friday. The company has a market cap of $47.46 billion, a PE ratio of 39.29, a price-to-earnings-growth ratio of 0.67 and a beta of 0.37. The stock has a 50-day moving average of $826.36 and a 200-day moving average of $811.97. argenex has a 52-week low of $510.05 and a 52-week high of $934.62.

argenex (NASDAQ:ARGX) last announced its earnings results on Thursday, February 26th. The company reported $8.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.05 by $1.97. argenex had a return on equity of 63.59% and a net margin of 30.42%.The firm had revenue of $1.32 billion during the quarter, compared to analysts’ expectations of $1.30 billion. On average, research analysts predict that argenex will post 3.13 earnings per share for the current year.

Institutional Trading of argenex

Institutional investors have recently made changes to their positions in the business. M&T Bank Corp raised its position in argenex by 20,977.7% in the 4th quarter. M&T Bank Corp now owns 778,610 shares of the company’s stock worth $654,772,000 after purchasing an additional 774,916 shares during the last quarter. Sands Capital Management LLC raised its position in shares of argenex by 2,046.6% during the fourth quarter. Sands Capital Management LLC now owns 356,870 shares of the company’s stock worth $300,110,000 after acquiring an additional 340,245 shares during the last quarter. Invesco Ltd. raised its position in shares of argenex by 390.4% during the fourth quarter. Invesco Ltd. now owns 416,408 shares of the company’s stock worth $350,178,000 after acquiring an additional 331,489 shares during the last quarter. Wellington Management Group LLP lifted its stake in shares of argenex by 80.1% during the third quarter. Wellington Management Group LLP now owns 729,986 shares of the company’s stock valued at $538,408,000 after acquiring an additional 324,653 shares during the period. Finally, Two Sigma Investments LP boosted its holdings in argenex by 570.3% in the third quarter. Two Sigma Investments LP now owns 294,160 shares of the company’s stock valued at $216,961,000 after acquiring an additional 250,278 shares during the last quarter. 60.32% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting argenex

Here are the key news stories impacting argenex this week:

• Positive Sentiment: Positive Phase‑3 topline results for VYVGART in ocular myasthenia gravis (ADAPT OCULUS); study met its primary endpoint and argenx plans a supplemental BLA submission to expand the label into oMG, which materially expands commercial opportunity. argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial
• Positive Sentiment: Strong quarterly and full‑year commercial performance: $1.3B in Q4 product net sales and $4.2B for FY2025 (≈90% YoY growth), reinforcing revenue momentum and the company’s commercialization traction. argenx Reports Full Year 2025 Financial Results
• Positive Sentiment: Q4 beat on the numbers: $8.02 EPS vs. $6.05 consensus and $1.32B revenue vs. $1.30B consensus, with healthy margins and ROE — data that supports higher earnings expectations. MarketBeat Q4 Earnings Summary
• Positive Sentiment: Certain sell‑side firms raised targets after the results (Citizens JMP and HC Wainwright among them), signaling continued analyst conviction in upside from commercialization and label expansion. These Analysts Revise Their Forecasts On Argenx After Q4 Earnings
• Neutral Sentiment: Other major firms trimmed price targets (Wells Fargo, Guggenheim, RBC) but generally maintained positive ratings (overweight/outperform/buy). These adjustments temper upside expectations but keep buy convictions intact. These Analysts Revise Their Forecasts On Argenx After Q4 Earnings
• Neutral Sentiment: Reports flag a “large increase” in short interest for February, but the published short‑interest numbers appear inconsistent/erroneous (zeros/NaN). As reported data is unreliable, the market impact is unclear.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.